<DOC>
	<DOCNO>NCT00026247</DOCNO>
	<brief_summary>RATIONALE : Radiofrequency ablation may effective decrease pain bone metastasis . PURPOSE : Phase I/II trial study effectiveness radiofrequency ablation decrease pain patient bone metastasis .</brief_summary>
	<brief_title>Radiofrequency Ablation Treating Patients With Bone Metastases</brief_title>
	<detailed_description>OBJECTIVES : - Determine side effect radiofrequency ablation patient bone metastasis . - Determine effect regimen pain patient . - Determine effect regimen mood patient . - Determine effect narcotic usage patient treat regimen . - Determine relationship laboratory image feature treatment effect treatment patient . OUTLINE : This multicenter study . Patients undergo percutaneous CT-guided radiofrequency ablation directly metastatic lesion approximately 12 minute . Pain mood assessed baseline , daily 14 day treatment , 1 3 month treatment . Patients follow 1 week 1 3 month . PROJECTED ACCRUAL : Approximately 75 patient accrue study within 12.5 month .</detailed_description>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm malignant disease bone lesion appear metastatic disease clinical and/or image technique Persistent intractable pain solitary site bone metastasis ( great 5 pain scale 010 ) Bone metastasis must amenable radiofrequency ablation use percutaneous CTguided approach Bone metastasis must great 8 cm No tumor mass contact hollow viscera No primary musculoskeletal malignancy , lymphoma , leukemia No spinal metastasis intact cortex mass spinal canal exit nerve root No tumor involve weightbearing long bone low extremity impending fracture PATIENT CHARACTERISTICS : Age : 21 Performance status : Not specify Life expectancy : Not specify Hematopoietic : Platelet count least 70,000/mm^3 No uncontrolled coagulopathy bleed diathesis correct fresh frozen plasma platelet Hepatic : Not specify Renal : Not specify Cardiovascular : No pacemaker PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : At least 14 day since prior chemotherapy metastatic disease No concurrent systemic chemotherapy metastatic disease 14 day study therapy Endocrine therapy : Not specify Radiotherapy : At least 30 day since prior radioisotope metastatic disease No concurrent systemic radioisotopes metastatic disease Surgery : No surgical stabilization tumor site metallic hardware Other : Prior aspirin , nonsteroidal antiinflammatory medication , antiplatelet medication , warfarin must discontinue appropriate period time prior study base drug 's halflife know antiplatelet activity ( e.g. , 7 day aspirin 24 hour ibuprofen ) At least 24 hour since prior low molecular weight heparin</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2006</verification_date>
	<keyword>bone metastasis</keyword>
	<keyword>pain</keyword>
	<keyword>unspecified adult solid tumor , protocol specific</keyword>
</DOC>